The Spanish Competition Authority fines drugmaker €10.25M for excessive pricing of a drug for the treatment of cerebrotendinous xanthomatosis (Leadiant)

XCT is an ultra-rare metabolic disease affecting 200-250 diagnosed patients in Europe of which around 50 are in Spain. XCT has

Access to this article is restricted to subscribers

Already Subscribed? Sign-in

Access to this article is restricted to subscribers.

Read one article for free

Sign-up to read this article for free and discover our services.

 

PDF Version

Author

  • Callol, Coca & Asociados (Madrid)

Quotation

Pedro Callol, The Spanish Competition Authority fines drugmaker €10.25M for excessive pricing of a drug for the treatment of cerebrotendinous xanthomatosis (Leadiant), 14 November 2022, e-Competitions November 2022, Art. N° 109764

Visites 58

All issues

  • Latest News issue 
  • All News issues
  • Latest Special issue 
  • All Special issues